(12) United States Patent (10) Patent No.: US 9,192,648 B2 Hamer Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US009 192648B2 (12) United States Patent (10) Patent No.: US 9,192,648 B2 Hamer et al. (45) Date of Patent: Nov. 24, 2015 (54) METHOD OF TREATING MYASTHENIA WO WO-2008/O2.9167 A1 3, 2008 GRAVIS WO WO-2008/029169 A2 3, 2008 WO WO-2009/098454 A2 8, 2009 (75) Inventors: John Hamer, Reading (GB); Wynne Weston-Davies, Reading (GB) OTHER PUBLICATIONS Copland etal. (2010)Systemic and local anti-C5 therapy reduces the (73) Assignee: Volution Immuno Pharmaceuticals SA disease severity in experimental autoimmune uveoretinitis, Clin. (CH) Exp. Immunol., vol. 159, No. 3, pp. 303-314.* Piddlesden et al. (1996) Soluble complement receptor 1 (SCR1) (*) Notice: Subject to any disclaimer, the term of this protects against experimental autoimmune myasthenia gravis, J. patent is extended or adjusted under 35 Neuroimmunol., vol. 71, No. 1-2, pp. 173-177.* U.S.C. 154(b) by 1397 days. Hsu et al. (2003) Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a (21) Appl. No.: 11/991,690 therapeutic role for complement inhibiton, J. Am. Soc. Nephroi., vol. 14, S186-S191.* Takata et al. (1987) Covalent association of C3b with C4b within C5 (22) PCT Filed: Sep. 5, 2006 convertase of the classical complement pathway, Exp. Med., vol. 165, No. 6, pp. 1494-1507.* (86). PCT No.: PCT/GB2OO6/OO3265 Honor Society of Nursing (2011, updated) "Can Myasthenia gravis S371 (c)(1), be preventable'?”, www.sharecare.com/question/can-myasthenia (2), (4) Date: Mar. 30, 2009 gravis-be-prevented, pp. 1-3. Article Sphere.com (2011, updated) “The Effects of Physiotherapy on Neurological Conditions', www.articlesphere.com/Article/The (87) PCT Pub. No.: WO2007/028968 Effects-of-Physiotherapy-on-Neurological-Conditions/208837, pp. PCT Pub. Date: Mar. 15, 2007 1-4. Xu et al. (2012) Divergenece of duplicate genes in exon-intron struc (65) Prior Publication Data ture, Proc. Natl. Acad. Sci. USA, 1109047109, Early Edition, pp. 1-6. US 2009/0209459 A1 Aug. 20, 2009 Banda et al. (2002) Mechanisms of effects of complement inhibition in murine collagne-induced arthritis, Arthr. Rheumatism, vol. 46, pp. (30) Foreign Application Priority Data 3065-3075. Christadoss, “C5 gene influences the development of murine Sep. 9, 2005 (GB) ................................... O518443.7 myasihenia gravis'. The Journal of Immunology, 1988, vol. 140, No. 8, pp. 2589-2592. Excerpt from The Merck Manual, 1999, pp. 1500-1501; and English (51) Int. Cl. translation thereof. A6 IK38/17 (2006.01) Harris et al., “Coupling complement regulators to immunoglobulin A61 K38/00 (2006.01) domains generates effective anti-complement reagents with extended (52) U.S. Cl. half-life in vivo”. Clin Exp Immunol. 2002, 129, 198-207. CPC ...................................... A61K 38/17 (2013.01) Hepburn et al., “Prevention of experimental autoimmune myasthenia (58) Field of Classification Search gravis by rat Crry-Ig: A model agent for long-term complement CPC ............................................... C12N2O15/8563 inhibition in vivo”. Molecular Immunology, 2008, 45, 395-405. See application file for complete search history. Nunnet al., “Complement inhibitor of C5activation from the soft tick Ornithodorus moubata'. The Journal of Immunology, 2005, 174. 2084-2091. (56) References Cited Richman et al., “Antibody effector mechanisms in myasthenia gravis U.S. PATENT DOCUMENTS The complement hypothesis'. Annals of the New York Academy of Sciences, 1998, 450-465. 5,041,389 A * 8, 1991 Lindstrom .................... 436,518 5,858,969 A * 1/1999 Marsh et al. ... 514/15 (Continued) 6,103,748 A * 8/2000 Bryan ........................... 514,400 7,884,066 B2 2/2011 Ting 7,884,069 B2 2/2011 Schaebitz et al. Primary Examiner — Manjunath Rao 2004/0014782 A1 1/2004 Krause .......................... 514/313 Assistant Examiner — Samuel Liu 2007/0048248 A1 3f2007 Benedict et al. ............. 424/78.3 2007/O141573 A1 6, 2007 Nunn (74) Attorney, Agent, or Firm — Choate, Hall & Stewart 2008.0114055 A1 5/2008 Kiss .............................. 514,437 LLP, Fangli Chen; Stephanie L. Schonewald 2008/O199484 A1* 8, 2008 Yu et al. ..................... 424,184.1 2010, O105611 A1 4/2010 Hamer 2011/0059885 A1 3/2011 Lea et al. (57) ABSTRACT FOREIGN PATENT DOCUMENTS The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associ WO WO-93/17099 A1 9, 1993 WO WO2004 106369 A2 * 12/2004 ated with inappropriate complement activation, and in par WO 2005O23866 3, 2005 ticular in the treatment of myasthenia gravis. WO 2005079363 9, 2005 WO WO-2007/028968 A1 3, 2007 WO WO-2007.117241 A1 10, 2007 14 Claims, 18 Drawing Sheets US 9,192,648 B2 Page 2 (56) References Cited Jarvis et al., IgM rheumatoid factor and the inhibition of covalent binding of C4b to IgG in immune complexes, Clinical Experimental OTHER PUBLICATIONS Rheumatology, 11:135-141 (1993). Keller et al., Cloning of the cDNA and Expression of Moubatin, an Sahu et al., "Complement inhibitors: a resurgent concept in anti Inhibitor of Platelet Aggregation, Journal of Biological Chemistry, inflammatory therapeutics”. Immunopharmacology, 2000, 49, 133 268:5450-5456 (1993). Kontinen et al., Complement in acute and chronic arthritides: assess 148. ment of C3c. C9 and protectin (CD59) in synovial membrane, Ann. Soltys et al., “Novel complement inhibitor limits severity of experi Rheum. Dis. 55: 888-894 (1996). mentally myasthenia gravis'. Ann Neurol, 2009, 65, 67-75. Kopf. M. et al., Complement component C3 promotes T-cell priming Asghar et al., Inhibition of Complement by a Series of Substituted and lung migration to control acute influenza virus infection, Nature 2-Aryl-1, 3-Indandiones: Interaction with the Fifth Component of Medicine, 8:373-378 (2002). Complement, Molecular Immunology, 23:459-465 (1986). Kroshus et al., A recombinant soluble chimeric complement inhibitor Astigarraga et al., Host immune response evasion strategies in composed of human CD46 and CD55 reduces acute cardiac tissue Ornithodoros erraticus and O. moubata and their relationship to the injury in models of pig-to-human heart transplantation, Transplanta development of an antiargasid vaccine, Parasite Immunology, tion, 69:2282-2289 (2000). 19:401-410 (1997). Köhl, J., Anaphylatoxins and infectious and non-infectious inflam Bao et al., Transgenic Expression of a Soluble Complement Inhibitor matory diseases, Molecular Immunology, 38; 175-187 (2001). Protects Against Renal Disease and Promotes Survival in MRUIpr Link et al., Selection of phage-displayed anti-guinea pig C5 or C5a Mice, Journal of Immunology, 168:3601-3607 (2002). antibodies and their application in Xenotransplantation, Molecular Baranda et al., Purification, N-terminal sequencing and diagnostic Immunology, 36:1235-1247 (1999). value of the major antigens of Ornithodoros erraticus and O. Mans et al., Identification of putative proteins involved in granule moubata, Veterinary Parasitology, 87: 193-206 (2000). biogenesis of tick salivary glands, Electrophoresis, 22:1739-1746 Bedford, J.M. and Witkin, S.S., Influence of complement depletion (2001). Mans et al., Pathogenic mechanisms of Sand tampan toxicoses on sperm function in the female rabbit, Journal of Reproductive induced by the tick, Ornithodoros savignyi, Toxicon, 40: 1007-1016 Fertility, 69:523-528 (1983). (2002). Biesecker, G. et al., Derivation of RNA aptamer inhibitors of human McKenzie et al., Regulation of Complement Activity by Vaccinia complement C5. Immunopharmacology, 42:219-230 (1999). Virus Complement-Control Protein, Journal of Infectious Diseases, Bumpers, H.L. and Baum, J., The Effect of a Novel C5 Inhibitor 166:1245-1250 (1992). (K-76 COONa) on Tumor Cell Chemotaxis, Journal of Laboratory Miletic, V.D. and Popovic, O.. Complementactivation in stored plate and Clinical Medicine, 102(3):421-427 (1983). let concentrates, Transfusion, 33: 150-154 (1993). Cicchetti et al., Combined Inhibition of Apoptosis and Complement Mulligan, M. et al., Endothelial Targeting and Enhanced Anti-inflam Improves Neural Graft Survival of Embryonic Rat and Porcine matory Effects of Complement Inhibitors Possessing Sialyl Lewis’ Mesencephalon in the Rat Brain, Experimental Neurology, 177:376 Moieties, Journal of Immunology, 162:4952-4959 (1999) 384 (2002). Paesen et al., Tick Histamine-Binding Proteins: Isolation, Cloning, Diamond et al., Human CD59 expressed in transgenic mouse hearts and Three-Dimensional Structure, Molecular Cell, 3:661-671 inhibits the activation of complement, 3:305-312 (1995). (1999). Ember et al., Characterization of Complement Anaphylatoxins and Paesen et al., Tick histamine-binding proteins: lipocalins with a sec Their Biological Responses, In: The Human Complement System in ond binding cavity, Biochimica et Biophysica Acta, 1482:92-101 Health and Disease, Volanakis, J.E., Frank, M.M. (Eds.), Marcel (2000). Dekker, New York, 241-284. Pratt et al., Effects of Complement Inhibition with Soluble Comple Evans et al. In Vitro and InVivo Inhibition of Complement Activity ment Receptor-1 on Vascular Injury and Inflammation during Renal by a Single-chain Fv Fragment Recognizing human C5, Molecular Allograft Rejection in the Rat, American Journal of Pathology, 149:2055-2066 (1996). Immunology, 32(16): 1183–1195 (1995). Rehrig et al., Complement Inhibitor, Complement Receptor 1-Re Fecke et al., Protection of hDAF-transgenic porcine endothelial cells lated Gene/Protein y-lg—Attenuates Intestinal Damage After the against activation by human complement: role of the membrane Onset of Mesenteric